Positive top-line Phase III data testing Puma Biotechnology Inc.'s Nerlynx (neratinib) in third-line HER2-positive metastatic breast cancer, released this week will lead to talks with US and European regulators and follow-up filings for approval in that indication by next July, according to the biotech's CEO.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?